Sandoz announces European Commission grants marketing authorization for Pyzchiva
Sandoz, the global leader in generic and biosimilar medicines, announces that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab), developed and registered by Samsung Bioepis. Pyzchiva is a key biosimilar …